Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 200 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $15.39 million which missed the analyst consensus estimate of $15.50 million by 0.72 percent. This is a 6.10 percent increase over sales of $14.50 million the same period last year.